Gefitinib, erlotinib and afatinib are three widely used epidermal growth factor receptor
tyrosine kinase inhibitors (EGFR TKIs) for treating advanced non‐small cell lung cancer …

Lung cancer represents the most common cause of brain dissemination. Oncogene-
addicted (EGFR-and ALK-positive) non-small cell lung cancers (NSCLCs) are characterized …

Background Amivantamab-lazertinib significantly prolonged progression-free survival (PFS)
versus osimertinib in patients with epidermal growth factor receptor (EGFR)-mutant …

Non-small cell lung cancer (NSCLC) is one of the most common malignant tumors and has
high morbidity and mortality rates. Central nervous system (CNS) metastasis is one of the …

Background Many patients with brain metastases from non-small cell lung cancer have
limited survival, while others survive for several years, depending on patterns of spread …

Opinion statement Management of non-small cell lung cancer (NSCLC) with brain
metastasis (BrM) has been revolutionized by identification of molecular subsets that have …

Background The first-generation epidermal growth factor receptor tyrosine kinase inhibitors
gefitinib and erlotinib have both been proven effective for treating advanced non–small cell …

Background and purpose According to the recent TNM 8 classification, patients with
metastatic non-small cell lung cancer (NSCLC) and single extrathoracic metastasis should …

Background: The epidermal growth factor receptor tyrosine kinase inhibitors gefitinib and
erlotinib are effective for advanced non-small cell lung cancer (NSCLC). This meta-analysis …

Brain metastases (BMs) are frequently occurred in lung adenocarcinoma with driver
mutation. There is a need to explore multi-discipline treatments and prognostic factors in …